2ⁿᵈ Edition of the Cancer R&D World Conference 2026

Scientific Sessions

Next Generation Cell and Gene Therapies in Oncology

Next-generation cell and gene therapies are revolutionizing cancer treatment by targeting the disease at its genetic and cellular roots. These cutting-edge approaches integrate advanced gene-editing tools, synthetic biology, and precision delivery systems to reprogram immune and tumor cells for lasting therapeutic benefit. Innovations such as CAR-T and TCR-engineered cells, oncolytic viruses, and gene-modified stem cells are offering unprecedented potential to achieve durable remissions and overcome resistance to conventional therapies. The convergence of genomics, artificial intelligence, and personalized medicine is accelerating the development of safer, more effective treatment strategies tailored to individual patients.

In this session at the Cancer Research and Development Conference 2026, exciting breakthroughs that will lead the next wave of cell and gene therapies in oncology will be highlighted. The latest clinical progress, regulatory considerations, and technological advancements that are driving this fast-emerging field will be deliberated upon. Join us as we explore how innovation, precision, and transformational science are reshaping the future of cancer care with next-generation therapeutic platforms.

Related Sessions

Current Landscape and Future Directions of Oncology Research
Oncogenic Signaling Pathways and Therapeutic Targets
Emerging Biomarkers for Cancer Detection and Prognosis
Cancer Prevention and Early Detection Strategies
Immuno Oncology and Cell Based Therapies
Innovations in Immuno Oncology
Cytokine Modulation and Immune Adjuvants in Cancer Immunotherapy
Cancer Vaccines
CAR T Cell Therapy: Clinical Progress and Challenges
Next Generation Cell and Gene Therapies in Oncology
Liquid Biopsy and Circulating Tumor DNA (ctDNA) Diagnostics
Companion Diagnostics
Artificial Intelligence and Machine Learning in Precision Oncology
Next Generation Targeted Therapies: KRAS, HER2, BRAF, and NRAS
Overcoming Drug Resistance: Mechanisms and Solutions
Oncology Pipeline
Trends in Antibody Drug Conjugates (ADCs)
Launch of Novel mAb Products for Cancer Therapy